Underland et al [23] performed a randomised, double-blinded, placebo-controlled study to assess the role of 100 mg of sitagliptin as an add-on therapy in type 1 diabetes with an insulin-only closed-loop system for 25 h with timed meals. The gene discussed is INS; the disease is type 1 diabetes mellitus.